Mounjaro Compounding Legal Status: What Patients and Prescribers Need to Know in 2025

Is compounded tirzepatide still legal?

Compounding is not banned outright, but the broad permission that existed during the shortage is gone. A state-licensed pharmacy may compound a drug for an identified patient on a prescription, as long as it does not make products that are essentially copies of a commercially available drug regularly or in inordinate amounts [1].

FDA treats a compounded product as essentially a copy when it contains the active ingredient of the commercially available drug in the same, similar, or easily substitutable strength and the same route of administration, unless a prescriber documents a significant difference for an identified patient [1]. Separately, FDA says it does not intend to take action against a compounder for filling four or fewer prescriptions of that compounded product in a calendar month. That reflects FDA's stated enforcement intent, not an approval [1].

What changed on December 19, 2024

FDA's declaratory order of December 19, 2024 determined that the tirzepatide injection shortage was resolved. It replaced an October 2, 2024 decision that a court had remanded for reevaluation [1].

The transition periods that had let compounders keep making tirzepatide then ran out: for state-licensed pharmacies the period of enforcement discretion ended after a court denied a preliminary injunction on March 5, 2025, and for outsourcing facilities it ended on March 19, 2025 [1].

What registered outsourcing facilities can do

Outsourcing facilities work under different rules from state-licensed pharmacies. They may compound without an individual patient prescription, including in response to an order from a health care provider for office stock, they are subject to current good manufacturing practice requirements, and FDA inspects them on a risk-based schedule [4].

They are restricted from compounding from bulk drug substances unless the substance appears on FDA's list of bulk substances for which there is a clinical need, or the drug being compounded is on FDA's shortage list at the time of compounding, distribution and dispensing [1]. FDA states that tirzepatide does not currently appear on either list [1].

The April 2026 proposal on bulk tirzepatide

On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound with, having found no clinical need for those substances [2]. Comments were accepted through June 29, 2026, and the agency said it would consider them before making a final determination [2]. The proposal is not a final rule, and a final decision was not found [2].

What FDA says about the safety of compounded tirzepatide

Compounded drugs are not FDA approved, which means FDA does not review them for safety, effectiveness or quality before they are marketed [5]. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug [5].

As of May 31, 2026, FDA had received more than 730 adverse event reports for compounded tirzepatide, and the agency says reported events likely undercount the true number [5]. FDA also advises that multi-dose vials of compounded sterile drugs be discarded within 28 days of first use even if medicine remains, that a new sterile needle and syringe be used for each dose, and that an injectable GLP-1 that arrives warm or with insufficient refrigeration not be used because quality may be affected [5].

What the Mounjaro label covers

Mounjaro is tirzepatide, a once-weekly subcutaneous injection and a dual GIP and GLP-1 receptor agonist [3]. The label's indications are glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes, and reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them [3]. Mounjaro is not labeled for weight loss; weight management is a Zepbound indication [3].

The label gives a starting dose of 2.5 mg once weekly, increased in 2.5 mg steps after at least 4 weeks on the current dose if more glycemic control is needed, to a maximum of 15 mg weekly in adults and 10 mg weekly in patients 10 years and older [3]. The boxed warning describes thyroid C-cell tumors in rats, with human relevance unknown, and the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

The label describes the approved manufactured product. The rules for compounded versions come from the federal compounding provisions and FDA's stated enforcement policies, not from the label [1].